Table 1

Characteristics of Carriers of LCAT Gene Mutations and Controls

Carriers of LCAT Gene Mutations (n = 40)Controls (n = 40)p Value
Characteristics
 Age, yrs42.4 ± 13.042.3 ± 14.10.97
 Male27 (68)23 (58)0.36
 Body mass index, kg/m225.7 ± 4.024.5 ± 3.50.17
 Smokers6 (15)6 (15)1.0
 Alcohol use, U/week5.8 ± 5.57.8 ± 7.90.22
Medication use
 Statin11 (28)1 (3)0.05
 Ezetimibe3 (8)0 (0)0.08
 Niacin3 (8)0 (0)0.08
 Fibrate1 (3)0 (0)0.31
 Aspirin3 (0)0 (0)0.08
Blood pressure, mm Hg
 Systolic131 ± 13128 ± 130.29
 Diastolic78 ± 976 ± 90
 Hypertension10 (25)6 (15)0.26
Glucose metabolism
 Fasting glucose, mmol/l5.2 ± 0.85.3 ± 0.90.49
 Fasting insulin, mU/l5.1 ± 8.95.2 ± 7.30.94
 HOMA index1.2 ± 2.11.5 ± 2.40.67
 Diabetes0 (0)1 (3)0.31
Lipid metabolism0.04
 Total cholesterol, mg/dl175.4 ± 44.1190.8 ± 41.6
 LDL-C, mg/dl126.5 ± 33.4123.6 ± 31.40.69
 HDL-C, mg/dl34.1 ± 13.954.4 ± 16.2<0.001
 Triglycerides, mg/dl104.4 (80.8–146.2)82.3 (55.3–126.1)0.06
 Apolipoprotein B, mg/dl103.1 ± 25.6100.7 ± 23.80.68
 Apolipoprotein A-I, mg/dl119.9 ± 31.9150.6 ± 25.7<0.001
 LCAT activity, nmol · ml−1 · h−19.24 ± 2.9512.85 ± 2.92<0.001

Values are mean ± SD or n (%). Male sex, smokers, medication use, hypertension, diabetes: p value for chi-square test; for other parameters: p for Student t test. Hypertension was defined as systolic blood pressure >140 mm Hg, diastolic blood pressure >90 mm Hg, or the use of antihypertensive medication. For triglycerides, we report the median and interquartile range; p value for t test after log-transformation.

HDL-C = high-density lipoprotein cholesterol; HOMA index = Homeostatic Model Assessment index; LCAT = lecithin:cholesterol acyltransferase; LDL-C = low-density lipoprotein cholesterol.